Heparin Reversal for Coronary Artery Perforation

• Published in: Catheterization and cardiovascular interventions 2024-12
• Main Authors: Sawayama, Yuichi, Sasaki, Kenta, Taninobu, Narumi, Ikuta, Akihiro, Osakada, Kohei, Kubo, Shunsuke, Tada, Takeshi, Fuku, Yasushi, Tanaka, Hiroyuki, Nakagawa, Yoshihisa, Kadota, Kazushige
• Format: Article
• Language: English
• ISSN: 1522-726X; 1522-726X
• DOI: 10.1002/ccd.31339

Reversing heparin when managing coronary artery perforation (CAP) during percutaneous coronary intervention (PCI) can provide hemostasis but may cause coronary thrombosis if a device is still present in a coronary artery. To assess the impact of heparin reversal while an intracoronary artery device is in place for CAP. This study analyzed CAP cases during PCI from January 2006 to October 2023. Patients were grouped according to implementing heparin reversal while an intracoronary artery device was in place. The safety outcome was coronary thrombosis after CAP. The efficacy outcomes were successful hemostasis and death from any cause. CAP occurred in 368 of 22,368 cases (1.6%). Patients who had heparin reversal with a device in place comprised 211 (57%). Among these, coronary thrombosis occurred in 16 (7.6%). An activated clotting time (ACT) 〈150 seconds was significantly correlated with coronary thrombosis. Heparin reversal with a device in place was significantly associated with successful hemostasis (heparin reversal 91% vs. no heparin reversal 73%; adjusted odds ratio 2.78; 95% confidence interval 1.27-6.13; p = 0.011), but was not different for death from any cause (heparin reversal 4.3% vs. no heparin reversal 5.7%; adjusted odds ratio 0.97; 95% confidence interval 0.28-3.43; p = 0.964). Heparin reversal with a device in place was associated with an increased risk of coronary thrombosis when ACT was less than 150 seconds. While it may not have a substantial association with a reduced risk of mortality, it offers an advantage in achieving successful hemostasis.